论文部分内容阅读
单克隆抗体技术的开发给肿瘤研究开辟了新的前景.用这一方法已使为数众多的肿瘤标志物显示了出来,有助于肿瘤的诊断.糖链抗原(Carbohydrate Antigen)CA19-9是有临床应用价值的最早发现的一个标志物,稍后即发现了CA125,两者均已经制成药盒,商品化供应.国际上已广泛应用,国内近年来亦开始引进.一、CA 19-9(一)CA19-9的性质 CA19-9是1979年由Koprowski等用结肠癌培养细胞株SW1116免疫小鼠,取其脾细胞制成杂交瘤,经筛选得到的单克隆抗体所识别的抗原.这
The development of monoclonal antibody technology has opened up new prospects for cancer research. With this method, a large number of tumor markers have been shown to help diagnose tumors. Carbohydrate Antigen CA19-9 is available One of the earliest discoveries of clinical application value was later discovered CA125, both of which have been manufactured into kits and commercialized supplies. It has been widely used internationally and has been introduced domestically in recent years. I. CA 19-9 (a) The nature of CA19-9 CA19-9 was immunized by Koprowski et al. in colon cancer cell line SW1116 in 1979. The spleen cells were used to prepare hybridomas and the antigens recognized by the screening monoclonal antibodies.